Back to search results

Aimovig Pregnancy Exposure Registry for Migraine

This study is an observational registry looking at pregnant women with migraine. It aims to understand if there's a difference in major birth defects in babies born to mothers who used erenumab-aooe (a monoclonal antibody medication for migraine) during pregnancy compared to those who didn't. You can join if you are 18 or older, currently pregnant, have a confirmed migraine diagnosis, and the outcome of your pregnancy is not yet known. The study will measure the number of babies experiencing major birth defects up to 52 weeks after birth. The study is currently unclear on its recruitment status and plans to include about 2842 women.

Study design
This is an observational study, meaning researchers will collect information without giving you a specific treatment. It aims to include about 2842 women.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will follow up to measure major birth defects in infants up to 52 weeks after birth.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06150781

Aimovig Pregnancy Exposure Registry

Recruiting
Not specifiedAges 18–99Observational
Amgen
~2,842 participants
Updated 2025-11-04 on ClinicalTrials.gov
What's tested:erenumab-aooe

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Infants Experiencing Major Congenital Malformations
Measured over Up to 52 Weeks

Conditions

Migraine

Explore related trials

Migraine

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

Amgen Call Center
[email protected]
866-572-6436
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older (at time of signing the informed consent)
Currently pregnant
The outcome of the pregnancy must not be known
Confirmed clinical diagnosis of migraine

Exclusion

Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded.
Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody \[mAb\] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy.

What this trial measures

  • Number of Infants Experiencing Major Congenital MalformationsUp to 52 Weeks